What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?  

I don’t know if those have been detailed from the BRUIN study.

The patients with CLL enrolled in the BRUIN study were heavily pre-treated with a median number of 3 prior therapies. All the patients in the BRUIN study had prior exposure to covalent BTK inhibitors and 40% of them also had been treated with a BCL2 inhibitor. As expected for patients...

I don’t think the post-protocol therapy data in the BRUIN trial have been disclosed yet.